IMPACT OF THE FREQUENCY OF USING NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON THE RADIOGRAPHIC PROGRESSION OF SACROILIITIS IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS

Objective: to compare the impact of continuous or on-demand use of nonsteroidal anti-inflammatory drugs (NSAIDs) on the activity and radiographic progression of early axial spondyloarthritis (axSpA).

Subjects and methods. The investigation enrolled patients from the early spondyloarthritis cohort who met the 2009 Assessment of Spondyloarthritis International Society (ASAS) criteria for axSpA. This analysis included 68 patients who had been followed up for at least 24 months. The mean age at the time of inclusion in the investigation was 28.5±5.8 years; the mean disease duration was 24.1±15.4 months; 63 (92.6%) patients were HLA-B27-positive. The patients were divided into two groups: 1) 35 patients used NSAIDs at maximum therapeutic doses continuously during the follow-up period; 2) 33 patients received these drugs on-demand, depending on the presence and severity of back pain.

Results and discussion. After 2-year follow-up, the median stage of radiographic sacroiliitis (SI) in Group 1 was unchanged and remained equal to 4; that in Group 2 in this period significantly increased from 3 to 4 scores (p < 0.05). At baseline, the patient groups did not differ in C-reactive protein (CRP) levels, the Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP), and the Bath Ankylosing Spondylitis Functional Index (BASFI); however, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was higher in Group 1 (p < 0.05). The number of patients with active SI, as evidenced by magnetic resonance imaging (MRI), and the degree of its severity did not differ significantly between groups. After 2 years, all the patients retained low disease activity according to ASDAS-CRP, BASDAI, and CRP levels; and these measures did not differ significantly between groups either; the BASFI became higher in Group 1. MRI findings indicated that the number of patients with active SI decreased, but no differences were found between the groups.

Conclusion. In patients with early axSpA, the continuous intake of NSAIDs can slow radiographic progression to a greater extent than their on-demand use. 

1. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. doi: 10.1136/ard.2009.108233

2. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73-84. doi: 10.1016/S0140-6736(16)31591-4

3. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis. Do we need new criteria? Arthritis Rheum. 2005;52(4):1000-8. doi: 10.1002/art.20990

4. Appel H, Sipper J. Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. Curr Rheumatol Rep. 2008;10(5):356-63. doi: 10.1007/s11926-008- 0058-x

5. Molto A, Paternotte S, van der Heijde D, et al. Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Ann Rheum Dis. 2015;74(4):746-51. doi: 10.1136/annrheumdis-2013-204262

6. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717-27. doi: 10.1002/art.24483

7. Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with nonradiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthr Care Res. 2012;64(9):1415-22. doi: 10.1002/acr.21688

8. Ciurea A, Scherer A, Exer P, et al. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65(12):3096-106. doi: 10.1002/art.38140

9. Эрдес ШФ, Дубинина ТВ, Румянцева ОА и др. Эволюция аксиального спондилоартрита за 12 месяцев наблюдения когорты КоРСАр. Научно-практическая ревматология. 2016;54(1S):55-9 [Erdes ShF, Dubinina TV, Rumyantseva OA, et al. The evolution of axial spondyloarthritis during 12-month follow-up study of a CORSAR cohort. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1S):55-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S55-59

10. Landewe R, Dougados M, Mielants H, et al. Physical function in AS is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863-7. doi: 10.1136/ard.2008.091793

11. Callhoff J, Sieper J, Weiss A, et al. Efficacy of TNFα blockers in patients with AS and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322

12. Румянцева ДГ, Дубинина ТВ, Демина АБ и др. Анкилозирующий спондилит и нерентгенологический аксиальный спондилоартрит: две стадии одной болезни? Терапевтический архив. 2017;89(5):33-7 [Rumyantseva DG, Dubinina TV, Demina AB, et al. Ankylosing spondylitis and non-radiographic axial spondyloarthritis: Two stages of disease? Terapevticheskiy Arkhiv. 2017;89(5):33-7 (In Russ.)]. doi: 10.17116/terarkh201789533-37

13. Lukas C, Landewe R, Sieper J, et al; Assessment of SpondyloArthritis International Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18-24. doi: 10.1136/ard.2008.094870

14. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388-98. doi: 10.1002/art.33465

15. Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114-8. doi: 10.1136/annrheumdis-2016-209209

16. Ramiro S, Stolwijk C, van Tubergen A, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74:52-9. doi: 10.1136/annrheumdis-2013-204055

17. Kroon F, Burg L, Ramiro S, et al. Non-steroidal anti-inflammatory drugs in axial spondyloarthritis: a Cochrane review. J Rheumatol. 2016;43(3):607-17. doi: 10.3899/jrheum.150721

18. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of nonsteroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616-22. doi: 10.1136/annrheumdis-2011-201252

19. Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623-9. doi: 10.1136/annrheumdis-2012- 201370

20. Wanders A, van der Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-65. doi: 10.1002/art.21054

21. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(2):1-44. doi: 10.1136/ard.2008.104018

22. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001;44(9):2112-7. doi: 10.1002/1529- 0131(200109)44:93.0.CO;2-H

23. Linden S, Valkenburg H, Cats A. Evaluation of Diagnostic Criteria for Ankylosing Spondylitis. Arthritis Rheum. 1984;27(4):361-8. doi: 10.1002/art.1780270401

24. Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70:249-51. doi: 10.1136/ard.2010.133488

25. Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi: 10.1136/annrheumdis-2016-210770

26. Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генноинженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84 [Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):474-84 (In Russ.)]. doi: 10.14412/1995- 4484-2017-474-484

27. Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3-17. doi: 10.1136/annrheumdis-2017-211734

28. Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Exp Rev Clin Immunol. 2015;11(8):935-46. doi: 10.1586/1744666X.2015.1052795

29. Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, doubleblind, controlled study. Ann Rheum Dis. 2008;67:323-9. doi: 10.1136/ard.2007.075309

30. Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109(11):1405-15. doi: 10.1172/JCI15681

31. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-infl ammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol. 2008;102:10-4. doi: 10.1111/j.1742- 7843.2007.00149.x